Ibrahim Bozyel

Ibrahim Bozyel

Auto-generated profile, based on publicly available information

Ibrahim Bozyel

Department of Electrical and Computer Engineering Worcester Polytechnic Institute Worcester Massachusetts USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2024 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
IBIbrahim Bozyel
Ibrahim Bozyel
DFDerek Fleming
Derek Fleming
KWKim Won-Jun
Kim Won-Jun
PRPeter F. Rosen
Peter F. Rosen
SGSuzanne Gelston
Suzanne Gelston
HBHaluk Beyenal
Haluk Beyenal

15 April 2025 in Biotechnology and Bioengineering
Verified
Journal Article
Open access
MAMajid Al‐Qurahi
Majid Al‐Qurahi
DFDerek Fleming
Derek Fleming
WKWon‐Jun Kim
Won‐Jun Kim
IBIbrahim Bozyel
Ibrahim Bozyel
RPRobin Patel
Robin Patel
HBHaluk Beyenal
Haluk Beyenal
Intraluminal infection of central venous catheters, used for long‐term treatment, can result in central line‐associated bloodstream infection (CLABSI). These infections can be challenging to prevent and treat due to formation of biofilms within catheter lumens, which shield bacteria from the human immune response and conventional antimicrobial therapies. Preventing bacterial colonization of catheter hubs is a strategy to prevent CLABSI. To address this, we developed a nonantibiotic, animal‐ready electrochemical catheter hub (e‐catheter hub), operated by a wearable, battery‐powered micropotentiostat (MP), that internally generates tunable hypochlorous acid (HOCl) for preventing intraluminal infection. The design evaluated three different electrode materials—titanium, platinum, and gold—for HOCl generation and biocidal activity, using working and counter electrodes of the same materials and a silver/silver chloride‐plated wire as a quasi‐reference electrode. e‐catheter hubs operated by MPs at 1.5 VAg/AgCl for 3 h generated HOCl, reducing Acinetobacter baumannii ATCC‐17978 below the detection limit (average reduction of 4.40 ± 0.05 log10 CFU/mL). The efficacy of e‐catheter hubs operated by MPs in generating HOCl and achieving biocidal activity is comparable to that of a commercial potentiostat. This study represents the first step in developing a localized, nonantibiotic strategy to mitigate CLABSI risk.

14 April 2025 in IEEE Sensors Reviews
Verified
Journal Article
Open access
AMAmr M. Maghraby
Amr M. Maghraby
IBIbrahim Bozyel
Ibrahim Bozyel
IAIslam T. Abougindia
Islam T. Abougindia
Suat Utku AySuat Utku Ay
Suat Utku Ay
The low-light performance of image sensors can be enhanced by designing high-effective conversion gain signal paths from photon conversion sites to chip outputs. This can be achieved by using high-gain in-pixel amplifiers, high-gain column amplifiers, and by reducing the conversion capacitance of photon sensing nodes. However, each of these approaches presents unique challenges and limitations that have restricted their widespread adoption in low-light applications. This paper reviews the use of in-pixel gain amplifiers and their signal chain electronics in high-conversion-gain CMOS image sensors over the past two decades. In-pixel gain amplifiers are classified into different categories according to the type of amplification technique used. Analyses of the column-referred conversion gain and the noise of each topology are presented alongside the different metrics used to characterize CMOS image sensor pixels for low-light imaging applications. The performance metrics of various in-pixel gain amplifiers are compared, providing a framework that highlights the best achieved input-referred noise in CMOS image sensors over the past fifteen years. Furthermore, different trade-offs are examined between optimizing conversion gain, pixel full-well capacity, and input read noise in both voltage and charge domains.

6 July 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WKWon-Jun Kim
Won-Jun Kim
IBIbrahim Bozyel
Ibrahim Bozyel
Suat Utku AySuat Utku Ay
Suat Utku Ay
MFMaren L. Friesen
Maren L. Friesen
HBHaluk Beyenal
Haluk Beyenal
Physicochemical soil parameters drive biogeochemical processes by controlling microbial activity and the mobility, solubility, and bioavailability of organic and inorganic matter. Because these properties vary with depth, depth-resolved electrochemical tools are needed, yet existing systems are often limited in travel range, automation, cost, or flexibility. Here, we present a custom-built Soil Electrochemical Profiling System (SEPS) for water-saturated soils and other conductive porous media. Built from off-the-shelf components, the custom manipulator hardware can be assembled for less than $200, provides up to 27 cm vertical travel, and operates with a minimum mechanical step interval of 25 μm. SEPS integrates with a potentiostat to perform open-circuit-potential-based redox profiling, cyclic voltammetry, and chronoamperometry. We tested the system using ferricyanide/ferrocyanide standards and hydrogel diffusion experiments. We then demonstrated proof-of-concept applications in homogenized, water-saturated soil mesocosms, where SEPS resolved time- and depth-dependent redox changes and voltammetric responses. In addition, a polarized carbon-tip electrode supported long-term biofilm enrichment and subsequent depth-resolved chronoamperometric measurements. SEPS provides a practical, low-cost platform for electrochemical profiling in saturated soils, hydrogels, sediments, and related porous media.

27 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
IBIbrahim Bozyel
Ibrahim Bozyel
DFDerek Fleming
Derek Fleming
WKWon-Jun Kim
Won-Jun Kim
PRPeter F. Rosen
Peter F. Rosen
SGSuzanne Gelston
Suzanne Gelston
HBHaluk Beyenal
Haluk Beyenal
Electrochemical bandages (e-bandages) can be applied to biofilm-infected wounds to generate reactive oxygen species, such as hypochlorous acid (HOCl) or hydrogen peroxide (H 2 O 2 ). The e-bandage-generated HOCl or H 2 O 2 kills biofilms in vitro and in infected wounds on mice. The HOCl-generating e-bandage is more active against biofilms in vitro , although this distinction is less apparent in vivo . The H 2 O 2 -generating e-bandage, more than the HOCl-generating e-bandage, is associated with improved healing of infected wounds. A strategy in which H 2 O 2 and HOCl are generated alternately—for dual action—was explored. The goal was to develop a programmable multimodal wearable potentiostat (PMWP) that could be programmed to generate HOCl or H 2 O 2 , as needed. An ultralow-power microcontroller unit managed operation of the PMWP. The system was operated with a 260-mAh capacity coin battery and weighed 4.6 grams, making it suitable for small animal experiments or human use. The overall cost of a single wearable potentiostat was $6.50 (USD). The device was verified using established electrochemical systems and functioned comparably to a commercial potentiostat. To determine antimicrobial effectiveness, PMWP-controlled e-bandages were tested against clinical isolates of four prevalent chronic wound bacterial pathogens, methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Acinetobacter baumannii , and Enterococcus faecium , and one fungal pathogen of emerging concern, Candida auris . PMWP-controlled e-bandages exhibited broad-spectrum activity against biofilms of all study isolates tested when programmed to deliver HOCl followed by H 2 O 2 . These results show that the PMWP operates effectively and is suitable for animal testing.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
DFDerek Fleming
Derek Fleming
DÖDilara Özdemir
Dilara Özdemir
JOJudith Alvarez Ortero
Judith Alvarez Ortero
MAMd Monzurul Anoy
Md Monzurul Anoy
MKMelissa Karau
Melissa Karau
RPRobin Patel
Robin Patel
Biofilms formed by antibiotic-resistant bacteria in wound beds present unique challenges in terms of treating wound infections. In this work, the in vivo anti-biofilm activity of a novel electrochemical bandage (e-bandage) designed to continuously deliver low amounts of hypochlorous acid (HOCl) was evaluated against wound biofilm infections caused by a clinical isolate of Pseudomonas aeruginosa resistant to all antibiotic classes except aminoglycosides. 5 mm skin wounds were created on the dorsal surface of Swiss-Webster mice and infected with 106 CFU of P. aeruginosa. Biofilms were allowed to form over 2 days, after which e-bandages with Tegaderm™ or Tegaderm only were placed on the wound beds. Specifically, mice were randomized to one of three experimental groups (n = 7-8): 1) Tegaderm only (control); 2) non-polarized e-bandage; 3) polarized e-bandage using a wearable potentiostat. After 48 hours, animals were sacrificed and 10 mm skin biopsies containing the wound and surrounding tissue were harvested for bacterial quantification. Histopathology was performed on H&E-stained sections of wound beds from each treatment group. Blood was screened with an inflammatory cytokine panel. Wound healing (% area reduction; digital measurement) and purulence (observational scoring) were assessed in pre- and post-treatment wounds. 48 hours of polarized e-bandage treatment resulted in a mean reduction of 1.86 log10 biofilm CFUs/g (p < 0.0001) vs non-polarized controls, and 2.18 log10 CFU/g reduction (p < 0.0001) vs Tegaderm only controls (polarized, 7.6 ± 0.66 log10 CFU/g; non-polarized, 9.45 ± 0.26 log+10 CFU/g; Tegaderm only, 9.78 ± 0.16 log10 CFU/g). Compared to Tegaderm only, purulence reduction and wound healing were significantly higher for both non-polarized (purulence - p < 0.0001; healing - p < 0.01 ) and polarized treatment (purulence - p < 0.0001; healing - p < 0.0001) groups, but were not significantly different from each other. Histopathology and blood inflammation panel testing showed no significant differences between groups. An HOCl-producing e-bandage reduced P. aeruginosa in wound biofilms, representing a potential antibiotic-free strategy for the treatment of recalcitrant wound infections. Audrey N. Schuetz, MD, Merck: Advisor/Consultant Robin Patel, MD, Abbott Laboratories: Advisor/Consultant|Adaptive Phage Therapeutics: Grant/Research Support|Adaptive Phage Therapeutics: Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics.|BIOFIRE: Grant/Research Support|CARB-X: Advisor/Consultant|ContraFect: Grant/Research Support|Day Zero Diagnostics: Advisor/Consultant|HealthTrackRx: Advisor/Consultant|Mammoth Biosciences: Advisor/Consultant|Netflix: Advisor/Consultant|Oxford Nanopore Technologies: Advisor/Consultant|PhAST: Advisor/Consultant|See details: Patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic|See details: continued, patent on an anti-biofilm substance issued|TenNor Therapeutics Limited: Grant/Research Support|Torus Biosystems: Advisor/Consultant|Trellis Bioscience, Inc.: Advisor/Consultant